Xanthopoulos A., Magouliotis D.E., Tryposkiadis K., Zotos P.-A., Spiliopoulos K., Athanasiou T., Giamouzis G., Skoularigis J., Starling R.C., Triposkiadis F. (2022)
Background: Despite the improvement in left ventricular assist device (LVAD) technology and the advent of third-generation LVADs, hemocompatibility-related events remain a significant issue. Therefore, new pharmacological ...